Low-dose aspirin (75-325 mg/day) increased the risk of gastrointestinal bleeding compared with placebo (OR 1.52; 95% CI 1.32-1.75).
Meta-Analysis
Does low-dose aspirin increase the risk of gastrointestinal bleeding in patients requiring prevention of ischemic, thromboembolic, or cerebrovascular events?
Low-dose aspirin (75-325 mg/day) significantly increases the risk of gastrointestinal bleeding by approximately 50% compared to placebo in patients receiving it for cardiovascular or cerebrovascular prevention.
Effect estimate: OR 1.52 (95% CI 1.32-1.75)
Low-dose aspirin has been recommended for primary and secondary prevention of myocardial infarction and for the maintenance of aortocoronary bypass patency. Doses as low as 75 mg/day significantly lessen the risk of stroke or death in patients who experience cerebrovascular and ischemic events. Aspirin in antiinflammatory doses has been associated with gastrointestinal bleeding, and the bleeding potential of even 75 mg aspirin has been established. I assessed the role of low-dose aspirin in gastrointestinal bleeding by combining the results of nine studies that dealt with the prevention of ischemic, thromboembolic, or cerebrovascular events. The combination of the results showed that the occurrence of bleeding was 1.5 times higher in patients treated with low-dose aspirin in doses of 75-325 mg/day as compared with placebo (odds ratio 1.52; 95% CI 1.32-1.75). The monthly probability of gastrointestinal bleeding per 1,000 patients treated with low-dose aspirin ranged between 0 and 2.1.
Stalnikowicz-Darvasi Ruth (Sat,) conducted a meta-analysis in Prevention of ischemic, thromboembolic, or cerebrovascular events. Low-dose aspirin vs. Placebo was evaluated on Gastrointestinal bleeding (OR 1.52, 95% CI 1.32-1.75). Low-dose aspirin (75-325 mg/day) increased the risk of gastrointestinal bleeding compared with placebo (OR 1.52; 95% CI 1.32-1.75).